OPDIVO

What OPDIVO does

OPDIVO is a prescription-only PD-1 (programmed death receptor-1) checkpoint inhibitor immunotherapy containing nivolumab, developed and marketed by Bristol Myers Squibb (NYSE: BMY). The drug works by blocking PD-1 receptors on T cells, preventing cancer cells from using PD-L1 to evade immune-mediated attack. It is FDA-approved for ten or more cancer indications, including advanced renal cell carcinoma (RCC), melanoma (advanced and adjuvant), non-small cell lung cancer (NSCLC), urothelial carcinoma, hepatocellular carcinoma, esophageal squamous cell and gastroesophageal junction cancer, gastric cancer, MSI-H/dMMR colorectal cancer, head and neck squamous cell carcinoma, and malignant pleural mesothelioma. The portfolio is anchored by two formulations: OPDIVO, a 30-minute intravenous infusion, and OPDIVO Qvantig, a 3–5 minute subcutaneous injection that combines nivolumab with hyaluronidase-nvhy to enable rapid absorption under the skin.

OPDIVO is used as monotherapy or in combination with YERVOY (ipilimumab, BMS's CTLA-4 inhibitor), CABOMETYX (cabozantinib, Exelixis), or platinum-based chemotherapy depending on the indication. Combination regimens are supported by large randomized trials, including 821-patient (CheckMate-025 vs everolimus), 651-patient (CheckMate 9ER vs sunitinib), and 847-patient (CheckMate 214 vs sunitinib) studies in advanced RCC, with reported overall survival and progression-free survival benefits of 27–49% versus standard-of-care comparators. OPDIVO Qvantig's pivotal subcutaneous trial enrolled 495 patients.

The commercial model is a sales-led, prescription pharmaceutical channel targeting oncologists and cancer specialists across doctor's offices, infusion centers, and hospital systems. Patients are routed through the OPDIVO with You support program and BMS Access Support for insurance coverage and co-pay assistance. Distribution is global where local regulatory approvals permit, with the input specifically identifying the United States as the primary served market. OPDIVO is a brand-level product within BMS; specific brand revenue is not disclosed in the supplied data.

Name

OPDIVO

Legal name

Bristol-Myers Squibb Company

Website

https://opdivo.com

Company type

Public

Founded year

2014

Operating status

Operating

Short description

OPDIVO is a Bristol Myers Squibb prescription immunotherapy (nivolumab, PD-1 inhibitor) and its subcutaneous variant OPDIVO Qvantig, approved for ten or more cancer types and administered to patients through oncologists, infusion centers, and hospitals.

Ownership category

akta.pro rank

Product category

Immuno-oncology pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIACAO

Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Immuno-oncology drugs
• PD-1 inhibitor therapy
• Cancer immunotherapy
• Oncology pharmaceuticals
• Prescription biologics

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

1. Prescription Pharmaceutical Sales: OPDIVO is a prescription-only immunotherapy drug sold to healthcare providers and patients through medical channels. Revenue is generated through product sales to hospitals, infusion centers, and specialty pharmacies. The product is administered in clinical settings or dispensed through specialty pharmacies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

OPDIVO is a prescription PD-1 inhibitor cancer immunotherapy (nivolumab) marketed by Bristol Myers Squibb, administered as a 30-minute intravenous infusion or as a 3-5 minute subcutaneous injection (OPDIVO Qvantig) across more than ten FDA-approved cancer indications. The drug is used alone or in combination with YERVOY (ipilimumab), CABOMETYX (cabozantinib), or chemotherapy, and is supported by the OPDIVO with You patient support program.

Product overview

OPDIVO is a pharmaceutical immunotherapy portfolio consisting of two FDA-approved cancer treatments: OPDIVO (nivolumab) administered as a 30-minute intravenous infusion, and OPDIVO Qvantig (nivolumab + hyaluronidase-nvhy) administered as a 3-5 minute subcutaneous injection. Both are PD-1 inhibitors that work with the immune system to fight cancer. OPDIVO is used alone or in combination with YERVOY (ipilimumab) or cabozantinib (CABOMETYX) across multiple cancer indications including kidney cancer, melanoma, lung cancer, bladder cancer, colorectal cancer, liver cancer, head and neck cancer, esophageal cancer, gastric cancer, and malignant pleural mesothelioma. The portfolio is complemented by the OPDIVO with You patient support program.

Differentiator

Problem solved

Functional benefit

Brands

• OPDIVO Qvantig: Subcutaneous injection formulation of nivolumab combined with hyaluronidase-nvhy for faster 3-5 minute administration compared to 30-minute IV infusion of OPDIVO.
• OPDIVO with You

Quantifiable outcome

• 27% lower risk of dying vs everolimus in previously treated advanced kidney cancer
• +6 more outcomes

Named customers10 records

Segments9 records

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• Tislelizumab - BeiGene: Tislelizumab is a PD-1 inhibitor developed by BeiGene that competes with OPDIVO in NSCLC, Hodgkin lymphoma, and gastric/esophageal cancers, particularly in Asia and increasingly in Western markets.
• Toripalimab (Tuoyi) - Junshi Biosciences: Toripalimab is a China-originated PD-1 inhibitor approved in nasopharyngeal carcinoma and other indications, representing a potential biosimilar/generic-style threat to OPDIVO in Asia-Pacific oncology markets.

Direct peers

• Keytruda (pembrolizumab) - Merck & Co. Merck's Keytruda is the leading PD-1 inhibitor and OPDIVO's most direct competitor across nearly every shared oncology indication, including NSCLC, RCC, melanoma, and gastric/esophageal cancers.
• Tecentriq (atezolizumab) - Genentech/Roche: Roche's Tecentriq is a PD-L1 checkpoint inhibitor that competes with OPDIVO in NSCLC, urothelial carcinoma, and hepatocellular carcinoma, sharing the same mechanism class and overlapping indications.
• Imfinzi (durvalumab) - AstraZeneca: AstraZeneca's Imfinzi competes with OPDIVO in NSCLC (PACIFIC regimen), urothelial carcinoma, and hepatocellular carcinoma, and is part of AZ's immuno-oncology combination strategy with tremelimumab.
• Bavencio (avelumab) - Pfizer/EMD Serono: Bavencio is a PD-L1 inhibitor approved in Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma, directly overlapping OPDIVO in metastatic and maintenance RCC settings.
• Libtayo (cemiplimab) - Regeneron/Sanofi: Libtayo is a PD-1 inhibitor approved in cutaneous squamous cell carcinoma, basal cell carcinoma, and NSCLC, positioning it as a smaller-scale direct competitor to OPDIVO in select oncology indications.

Others

• YERVOY (ipilimumab) - Bristol Myers Squibb: YERVOY is BMS's CTLA-4 inhibitor and the most important combination partner for OPDIVO, jointly indicated across RCC, melanoma, HCC, and ESCC.
• CABOMETYX (cabozantinib) - Exelixis: CABOMETYX is a tyrosine kinase inhibitor that combines with OPDIVO in first-line advanced RCC, representing a key combination partner and an adjacent oncology asset in the same indication.
• Bristol Myers Squibb (parent): BMS is the parent company of OPDIVO and the manufacturer of its combination partners (YERVOY, Opdivo Qvantig). As the broad incumbent in oncology and hematology, BMS provides commercial, manufacturing, and pipeline context for the OPDIVO franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPDIVO